These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8636010)

  • 1. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions.
    Oshita F; Kurata T; Kasai T; Fakuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Jpn J Cancer Res; 1995 Dec; 86(12):1198-202. PubMed ID: 8636010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
    Takada M; Fukuoka M; Ariyoshi Y; Furuse K; Niitani H; Ota K; Motomiya M; Hasegawa K; Tominaga K; Kuriyama T
    Cancer Chemother Pharmacol; 1992; 31(3):182-6. PubMed ID: 1281446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
    Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR;
    Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: a Hoosier Oncology Group phase II trial.
    Sandler A; Blanke C; Monaco F; Carey MA; Ansari R; Fisher B; Spiridonidis CH; Einhorn L; Nichols C
    Am J Clin Oncol; 1998 Jun; 21(3):294-7. PubMed ID: 9626802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. r-metHuG-CSF support to ifosfamide, cisplatin, etoposide chemotherapy in non-small cell lung cancer.
    Gautier V; Pujol JL; Zinaï A; Michel FB
    Lung Cancer; 1996 Jun; 14(2-3):343-51. PubMed ID: 8794415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
    Shepherd FA; Evans WK; Goss PE; Latreille J; Logan D; Maroun J; Stewart D; Warner E; Paul K
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):54-8. PubMed ID: 1329213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer.
    Nakanishi Y; Takayama K; Kawasaki M; Yatsunami J; Inutsuka S; Wakamatsu K; Tsuruta N; Hara N
    Am J Clin Oncol; 1997 Aug; 20(4):393-7. PubMed ID: 9256897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European experience with ifosfamide in non-small cell lung cancer.
    Drings P
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):22-30. PubMed ID: 2539645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-intensive chemotherapy with cisplatin, vincristine, doxorubicin and etoposide against lung cancer: a pilot study.
    Yanagawa H; Bando H; Takishita Y
    Anticancer Res; 1995; 15(2):613-6. PubMed ID: 7539241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.